Current Environment: Production

Medical Services

Programs & Services

Languages

  • English

Education

Medical School

David Geffen School of Medicine at UCLA

2008, Los Angeles, CA

Internship

Pediatrics

Lucile Packard Children’s Hospital at Stanford University

2009, Palo Alto, CA

Residency

Pediatrics

Lucile Packard Children’s Hospital at Stanford University

2011, Palo Alto, CA

Fellowship

Clinical Ethics

MacLean Center for Clinical Medical Ethics, University of Chicago

2012, Chicago, IL

Fellowship

Pediatric Hematology/Oncology

Boston Children’s Hospital/Dana-Farber Cancer Institute

2015, Boston, MA

Fellowship

Health Services Research

Harvard Medical School

2016, Boston, MA

Graduate School

MPH

Harvard T.H. Chan School of Public Health

2016, Boston, MA

Certifications

  • American Board of Pediatrics (General)

Professional History

Dr. Marron received his medical degree from the David Geffen School of Medicine at UCLA in 2008. He completed his residency in Pediatrics at Stanford University and his fellowship in Clinical Medical Ethics at the University of Chicago followed by his fellowship in Pediatric Hematology/Oncology at Boston Children’s Hospital and the Dana-Farber Cancer Institute. Dr. Marron also received an MPH in 2016 from the Harvard T.H. Chan School of Public Health. Jonathan cares for pediatric oncology patients in the inpatient setting at Boston Children’s Hospital and in the outpatient clinic at the Dana-Farber Cancer Institute. His research interests are in ethics and decision-making, health services, clinical genomics, informed consent, and medical uncertainty. Much of Dr. Marron’s current work focuses on patient, parent, and physician decision-making regarding pediatric precision cancer medicine. He also teaches medical ethics to medical students and graduate students through his role as teaching faculty at the Harvard Medical School Center for Bioethics.

Publications

  1. Growth Attenuation Therapy: Ongoing Ethical and Practical Challenges 20 Years Post Ashley. Am J Bioeth. 2025 May 23; 1-9. View Abstract

  2. Potentially Inappropriate Treatment: Competing Ethical Considerations. AACN Adv Crit Care. 2025 Mar 15; 36(1):30-36. View Abstract

  3. Parents' Experiences With and Preferences for Receiving Information About Tumor Genomic Sequencing: Findings From a Qualitative Study and Implications for Practice. JCO Precis Oncol. 2024 Dec; 8:e2400543. View Abstract

  4. Clinical ethics consultation services: public-facing information on NCI-designated cancer center websites. Oncologist. 2024 Oct 03; 29(10):904-907. View Abstract

  5. The Closing of an Academic Children's Hospital: Ethical Considerations for Graduate Medical Education. J Grad Med Educ. 2024 Aug; 16(4):395-398. View Abstract

  6. Everyday Clinical Ethics: Essential Skills and Educational Case Scenarios. HEC Forum. 2025 Jun; 37(2):179-201. View Abstract

  7. Perspectives of pediatric oncologists on referral for CAR-T therapy: a mixed methods pilot study. JNCI Cancer Spectr. 2024 Jul 01; 8(4). View Abstract

  8. Establishing and Defining an Approach to Climate Conscious Clinical Medical Ethics. Am J Bioeth. 2024 Apr 18; 1-14. View Abstract

  9. A Communication and Decision-Making Framework for Pediatric Precision Medicine. Pediatrics. 2024 Apr 01; 153(4). View Abstract

  10. Perspectives of Oncologists on the Ethical Implications of Using Artificial Intelligence for Cancer Care. JAMA Netw Open. 2024 03 04; 7(3):e244077. View Abstract

  11. Shifting from Equality toward Equity: Addressing Disparities in Research Participation for Clinical Cancer Research. J Clin Ethics. 2024; 35(1):8-22. View Abstract

  12. Prognosis-Based Definitions for Potentially Inappropriate Treatment: Still Flawed, If Not Futile. J Clin Ethics. 2024; 35(4):224-228. View Abstract

  13. ASCO Ethical Guidance for the Practical Management of Oncology Drug Shortages. J Clin Oncol. 2024 Jan 20; 42(3):358-365. View Abstract

  14. Hopes, concerns, satisfaction and regret in a precision medicine trial for childhood cancer: a mixed-methods study of parent and patient perspectives. Br J Cancer. 2023 11; 129(10):1634-1644. View Abstract

  15. Parents' and adolescents' perspectives and understanding of information about childhood cancer precision medicine. Cancer. 2023 11 15; 129(22):3645-3655. View Abstract

  16. Potentially Inappropriate Treatment: Competing Ethical Considerations. AACN Adv Crit Care. 2023 Jun 15; 34(2):161-167. View Abstract

  17. Can the Extraordinary Become Ordinary? Re-Examining the Ethics of ECMO-DT. Am J Bioeth. 2023 06; 23(6):59-61. View Abstract

  18. Clinical ethics consultation documentation in the era of open notes. BMC Med Ethics. 2023 05 03; 24(1):27. View Abstract

  19. Fear of Saying No (FOSNO): Setting Boundaries With Our Patients and Ourselves. Am Soc Clin Oncol Educ Book. 2023 May; 43:e390598. View Abstract

  20. Pediatric Brain Death Testing Over Parental Objections: Not an Ethically Preferable Option. Am J Bioeth. 2023 01; 23(1):90-93. View Abstract

  21. The role of ethicists in pediatric hematology/oncology: Current status and future needs. Pediatr Blood Cancer. 2023 02; 70(2):e30132. View Abstract

  22. Words Matter. J Clin Oncol. 2023 01 20; 41(3):706-707. View Abstract

  23. Parents' understanding of genome and exome sequencing for pediatric health conditions: a systematic review. Eur J Hum Genet. 2022 11; 30(11):1216-1225. View Abstract

  24. What's in a Name? Parents' and Healthcare Professionals' Preferred Terminology for Pathogenic Variants in Childhood Cancer Predisposition Genes. J Pers Med. 2022 Aug 18; 12(8). View Abstract

  25. Ethics Consultation in Oncology: The Search for Quality in Quantity. JCO Oncol Pract. 2022 09; 18(9):610-613. View Abstract

  26. A Process Framework for Ethically Deploying Artificial Intelligence in Oncology. J Clin Oncol. 2022 12 01; 40(34):3907-3911. View Abstract

  27. Ethics-Centered Guidelines for Social Media Use by Oncology Professionals: A Call to Action. JCO Oncol Pract. 2022 08; 18(8):537-540. View Abstract

  28. Could Behavioral Economics Mitigate Shortcomings in Shared Decision-Making? Perspect Biol Med. 2022; 65(3):469-483. View Abstract

  29. Picture a Professional: Rethinking Expectations of Medical Professionalism Through the Lens of Diversity, Equity, and Inclusion. J Clin Oncol. 2021 12 20; 39(36):4004-4008. View Abstract

  30. The Case of Billy Best: 25 Years Later. Pediatrics. 2021 09; 148(3). View Abstract

  31. Striving for equity: Patient prioritization during a critical cancer drug shortage. Pediatr Blood Cancer. 2021 11; 68(11):e29280. View Abstract

  32. Adolescent Shared Decision-Making: Where We Have Been and Where We are Going. J Adolesc Health. 2021 07; 69(1):6-7. View Abstract

  33. The Ethical Imperative of Equity in Oncology: Lessons Learned From 2020 and a Path Forward. Am Soc Clin Oncol Educ Book. 2021 Jun; 41:e13-e19. View Abstract

  34. Socioeconomic disparities in survival after high-risk neuroblastoma treatment with modern therapy. Pediatr Blood Cancer. 2021 10; 68(10):e29127. View Abstract

  35. The Complicated Legacy of Cassandra Callender: Ethics, Decision-making, and the Role of Adolescents. JAMA Pediatr. 2021 04 01; 175(4):343-344. View Abstract

  36. Structural Racism in the COVID-19 Pandemic: Don't Forget about the Children! Am J Bioeth. 2021 03; 21(3):94-97. View Abstract

  37. US State Government Crisis Standards of Care Guidelines: Implications for Patients With Cancer. JAMA Oncol. 2021 02 01; 7(2):199-205. View Abstract

  38. Ethical Challenges in Pediatric Oncology Care and Clinical Trials. Recent Results Cancer Res. 2021; 218:149-173. View Abstract

  39. Communicating uncertainty: A step in the right direction? Pediatr Blood Cancer. 2021 03; 68(3):e28849. View Abstract

  40. American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care. J Clin Oncol. 2021 01 10; 39(2):155-169. View Abstract

  41. Informed consent for genetic testing in hematology. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):213-218. View Abstract

  42. Waging War on War Metaphors in Cancer and COVID-19. JCO Oncol Pract. 2020 10; 16(10):624-627. View Abstract

  43. How should we approach parental refusals of opioids on behalf of children in the perioperative setting? A practical approach based on ethical theory. Paediatr Anaesth. 2020 08; 30(8):852-858. View Abstract

  44. Ethics and Resource Scarcity: ASCO Recommendations for the Oncology Community During the COVID-19 Pandemic. J Clin Oncol. 2020 07 01; 38(19):2201-2205. View Abstract

  45. A Call to Action: Ethics Committee Roundtable Recommendations for Addressing Burnout and Moral Distress in Oncology. JCO Oncol Pract. 2020 04; 16(4):191-199. View Abstract

  46. Medical Decision-Making in Oncology for Patients Lacking Capacity. Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-11. View Abstract

  47. Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement. J Clin Oncol. 2019 09 10; 37(26):2368-2377. View Abstract

  48. Stopping Leukemia in Its Tracks: Should Preemptive Hematopoietic Stem-Cell Transplantation be Offered to Patients at Increased Genetic Risk for Acute Myeloid Leukemia? J Clin Oncol. 2019 08 20; 37(24):2098-2104. View Abstract

  49. Ethical Issues Considered When Establishing a Pediatrics Gender Surgery Center. Pediatrics. 2019 06; 143(6). View Abstract

  50. Prognostication and Communication in Oncology. J Oncol Pract. 2019 04; 15(4):208-215. View Abstract

  51. Identification Before Prescription: Necessary Changes for the Support of Transgender Youth. Am J Bioeth. 2019 02; 19(2):78-80. View Abstract

  52. Duality of purpose: Participant and parent understanding of the purpose of genomic tumor profiling research among children and young adults with solid tumors. JCO Precis Oncol. 2019; 3. View Abstract

  53. Let's Talk About Those Herbs You Are Taking: Ethical Considerations for Communication With Patients With Cancer About Complementary and Alternative Medicine. J Oncol Pract. 2019 01; 15(1):44-49. View Abstract

  54. Justice in CRISPR/Cas9 Research and Clinical Applications. AMA J Ethics. 2018 09 01; 20(9):E826-833. View Abstract

  55. Not All Disagreements Are Treatment Refusals: The Need for New Paradigms for Considering Parental Treatment Requests. Am J Bioeth. 2018 08; 18(8):56-58. View Abstract

  56. Counterpoint: Provider moral distress in end-of-life oncology care is a moral crutch. Psychooncology. 2018 06; 27(6):1664-1666. View Abstract

  57. Intended and unintended consequences: Ethics, communication, and prognostic disclosure in pediatric oncology. Cancer. 2018 03 15; 124(6):1232-1241. View Abstract

  58. Is There Ever a Role for the Unilateral Do Not Attempt Resuscitation Order in Pediatric Care? J Pain Symptom Manage. 2018 01; 55(1):164-171. View Abstract

  59. Ethical considerations in genomic testing for hematologic disorders. Blood. 2017 07 27; 130(4):460-465. View Abstract

  60. Pediatric Oncology Provider Views on Performing a Biopsy of Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling. Ann Surg Oncol. 2016 12; 23(Suppl 5):990-997. View Abstract

  61. Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience. Pediatr Blood Cancer. 2016 11; 63(11):1974-82. View Abstract

  62. Against "Healthy Paternalism" at the End of Life. JAMA Oncol. 2016 Jun 01; 2(6):832. View Abstract

  63. Multimodality Treatment of Pediatric Esthesioneuroblastoma. Pediatr Blood Cancer. 2016 Mar; 63(3):465-70. View Abstract

  64. When to say when: How aggressively to care for children with multiply relapsed cancer? Pediatr Blood Cancer. 2015 Jul; 62(7):1119-20. View Abstract

  65. Physician attitudes toward industry: room for improvement. Arch Surg. 2010 Dec; 145(12):1213. View Abstract

  66. Ethical issues in innovative colorectal surgery. Dis Colon Rectum. 2005 Jun; 48(6):1109-13. View Abstract
BESbswy